C-Jun N-Terminal kinase mediates lactacystin-induced dopamine neuron degeneration

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 10, 2008, Pages 933-944

  Li, Xuping ^a   Du, Yunlan ^a   Fan, Xiaolan ^a   Yang, Dehua ^a   Luo, Guangrui ^a   Le, Weidong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; C Jun N terminal kinase; Dopamine neuron degeneration; Lactacystin; Parkinson disease; Ubiquitin proteasome system

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 9; CYTOCHROME C; LACTACYSTIN; STRESS ACTIVATED PROTEIN KINASE; ACETYLCYSTEINE; CYSTEINE PROTEINASE INHIBITOR; DOPAMINE; DRUG DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFUSION; MALE; NERVE CELL DEGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; ANIMAL; CELL LINE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYMOLOGY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; NERVE DEGENERATION; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ACETYLCYSTEINE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROMES C; DOPAMINE; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; NERVE DEGENERATION; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; TETRAZOLIUM SALTS; THIAZOLES;

EID: 54449091703     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318186de64     Document Type: Article

References (52)

1. Le WD, Appel SH. Mutant genes responsible for Parkinson's disease. Curr Opin Pharmacol 2004;4:79-84
2. Gandhi S, Wood NW. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005;14:2749-2755
3. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J Clin Invest 2006;7:1744-1754
4. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-144
5. Allam MF, del Castillo AS, Navajas RF. Parkinson's disease risk factors. Rev Neurol 2003;36:749-755
6. von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 2004; 73:151-177
7. Moore DJ, West AB, Dawson VL, et al. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57-87
8. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52
9. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006;7:207-219
10. McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 2006;27: 530-545
11. Burke RE. Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther 2007;114:261-277
12. McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002;81:301-306
13. Rideout HJ, Lang-Rollin IC, Savalle M, et al. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem 2005;93:1304-1313
14. Reaney SH, Johnston LC, Langston WJ, et al. Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp Neurol 2006;202:434-440
15. Zhang X, Xie WJ, Qu S, et al. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophy Res Commun 2005;333:544-549
16. Sun F, Anantharam V, Zhang D, et al. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 2006;27:807-15
17. Bove J, Zhou C, Jackson-Lewis V, et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 2006;60:260-264
18. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 2000;97:2875-2880
19. Tatton WG, Chalmers-Redman R, Brown D, et al. Apoptosis in Parkinson's disease: Signals for neuronal degradation. Ann Neurol 2003;53:S61-S70
20. Shavali S, Sens DA. Synergistic neurotoxic effects of arsenic and dopamine in human dopaminergic neuroblastoma SH-SY5- cells. Toxicol Sci 2008;102:254-261
21. Maruyama W, Sango K, Iwasa K, et al. Dopaminergic neurotoxins, 6,7-dihydroxy-1-(3ô, 4ô-dihydroxybenzyl)-isoquinolines, cause different types of cell death in SH-SY5- cells: Apoptosis was induced by oxidized papaverolines and necrosis by reduced tetrahydropapaverolines. Neurosci Lett 2000;291:89-92
22. Jellinger KA. Cell death mechanisms in Parkinson's disease. J Neural Transm 2000;107:1-29
23. Chun HS, Gibson GE, DeGiorgio LA, et al. Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem 2001;76:1010-1021
24. Peng J, Mao XO, Stevenson FF, et al. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J Biol Chem 2004;279:32626-32632
25. Lee DY, Oh YJ, Jin BK. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: Dual roles of mitogen-activated protein kinase signaling pathways. Glia 2005;51: 98-110
26. Silva RM, Kuan CY, Rakic P, et al. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: A new therapeutic target in Parkinson's Disease. Mov Disord 200;20:6535-6564
27. Saporito MS, Brown EM, Miller MS, et al. CEP-1347, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 1999;288:421-427
28. Ouyang M, Shen X. Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5- cells. J Neurochem 2006;97:234-244
29. Xia XG, Harding T, Weller M, et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 2001;98:10433-10438
30. Crocker SJ, Hayley SP, Smith PD, et al. Regulation of axotomy-induced dopaminergic neuron death and c-Jun phosphorylation by targeted inhibition of cdc42 or mixed lineage kinase. J Neurochem 2006;96:489-499
31. Li XP, Peng CG, Li L, et al. Glial cell-derived neurotrophic factor protects against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation. J Gerontol A Biol Sci Med Sci 2007;62:943-950
32. Nishitoh H, Matsuzawa A, Tobiume K, et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 2002;16:1345-1355
33. Sekine Y, Takeda K, Ichijo H. The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. Curr Mol Med 2006;6:87-97
34. Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's 2005;4:63-67
35. Becker EB, Bonni A. Pin1 mediates neural-specific activation of the mitochondrial apoptotic machinery. Neuron 2006;49:655-62
36. Okuno S, Saito A, Hayashi T, et al. The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia. J Neurosci 2004;24:7879-7887
37. Li X, Yang D, Li L, et al. Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures. Neurochem Int 2007;50:959-965
38. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York, NY: Academic Press, 1986
39. Eom DS, Choi WS, Ji S, et al. Activation of c-Jun N-terminal kinase is required for neurite outgrowth of dopaminergic neuronal cells. Neuro-report 2005;16:823-828
40. Lang-Rollin I, Vekrellis K, Wang Q, et al. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem 2004;90:1511-1520
41. Rawal N, Parish C, Castelo-Branco G, et al. Inhibition of JNK increases disease. survival of transplanted dopamine neurons in Parkinsonian rats. Cell Mov Disord 2005;20:653
42. Death Differ 2007;14:381-383
43. Gomez-Santos C, Barrachina M, Gimenez-Xavier P, et al. Induction of C/EBP beta and GADD153 expression by dopamine in human neuro-blastoma cells. Relationship with alpha-synuclein increase and cell damage. Brain Res Bull 2005;65:87-95
44. Bae JH, Jang BC, Suh SI, et al. Manganese induces inducible nitric oxide synthase (iNOS) expression via activation of both MAP kinase and PI3K/Akt pathways in BV2 microglial cells. Neurosci Lett 2006; 398:151-154
45. Choi HJ, Lee SY, Cho Y, et al. JNK activation by tetrahydrobiopterin: Implication for Parkinson's disease. J Neurosci Res 2004;75:715-721.
46. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-9704
47. Pei DS, Sun YF, Guan QH, et al. Postsynaptic density protein 95 antisense oligodeoxynucleotides inhibits the activation of MLK3 and JNK3 via the GluR6.PSD-95.MLK3 signaling module after transient cerebral ischemia in rat hippocampus. Neurosci Lett 2004;367:71-75
48. Xu Z, Kukekov NV, Greene LA. POSH acts as a scaffold for a multi-protein complex that mediates JNK activation in apoptosis. EMBO J 2003;22:252-261
49. Meriin AB, Gabai VL, Yaglom J, et al. Proteasome inhibitors activate diseases stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol therapy. Curr Drug Targets CNS Neurol Disord Chem 1998;273:6373-6379
50. Sang C, Kobayashi Y, Du J, et al. c-Jun N-terminal kinase pathway mediates lactacystin-induced cell death in a neuronal differentiated Neuro2a cell line. Brain Res Mol Brain Res 2002;108:7-17
51. Meller R, Cameron JA, Torrey DJ, et al. Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons. J Biol Chem 2006;281:7429-7436
52. Zhu W, Xie W, Pan T, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 2007;21:3835-3844